跳至主要内容
临床试验/CTRI/2023/04/051904
CTRI/2023/04/051904已完成4 期

An Open-labelled, Single Arm, Interventional Clinical Study to Evaluate the Efficacy and Safety of NATBERB (100% Natural Berberine) as an adjuvant therapy in Type 2 Diabetes mellitus

Herbal Creations (A Unit of Kumaon Exports Pvt. Ltd.)0 个研究点目标入组 46 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients of either sex between the age group 18 to 55 years(both inclusive).
  • 2. Patients who are diagnosed as suffering from Type 2 Diabetes mellitus.
  • 3. Patients with HbA1c = 7.0%.
  • 4. Subjects with Body Mass Index (BMI) >27 kg/m2 and <45 kg/m2.

排除标准

  • 1.Type 1 diabetes mellitus
  • 2.Patients with severe hyperglycemia (FBS >240 mg% or PPBS >360 mg%)
  • 3.Patients with fasting serum cholesterol >260mg%
  • and serum Triglycerides >300 mg%.
  • 4.Patients with HbA1c more than 10.5 %.
  • 5.Patients with ASAT and ALT levels greater than 2.5 times the upper normal limits
  • 6.Severe renal, hepatic or respiratory disorder.

研究者

发起方
Herbal Creations (A Unit of Kumaon Exports Pvt. Ltd.)

相似试验